Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd Q3 FY24 Results & Presentation Highlights: Revenue, Margins & Order Book
Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on Lincoln Pharmaceuticals Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
The presentation does not provide any revenue, sales, or volume figures for the quarter, nor does it mention any year-on-year changes or explicit outlooks for revenue or volumes. The presentation reports the following figures for the quarter: - EBITDA: ₹1,150 crore, showing a year-on-year increase of 34%.
From Lincoln Pharmaceuticals Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹187 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY24)
Net Sales Revenues for 9M FY24: INR 2,129 Cr. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY24 investor presentation — and how it ranks against
- NGL Fine Chem Ltd (Q3 FY24)
Q3FY24 Revenue from Operations: ₹87.95 crore, up 22.27% year-on-year (YoY) from Q3FY23 ₹71.93 crore (Page 8). Key investor presentation takeaways from NGL Fine
- Anuh Pharma Ltd (Q3 FY24)
172.10 Cr, a 15% increase quarter-on-quarter and 31% year-on-year over 9M FY23. Key investor presentation takeaways from Anuh Pharma Ltd's Q3 FY24 investor pres
- Bharat Parenterals Ltd (Q3 FY24)
Revenue from operations: ₹58.8 crore (down 0.4% YoY) . Key investor presentation takeaways from Bharat Parenterals Ltd's Q3 FY24 investor presentation — and how
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q3 FY24 results?
The presentation does not provide any revenue, sales, or volume figures for the quarter, nor does it mention any year-on-year changes or explicit outlooks for revenue or volumes. The presentation reports the following figures for the quarter: - EBITDA: ₹1,150 crore, showing a year-on-year increase of 34%.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
The presentation does not provide any specific details regarding capex, capacity expansion, new plants, or projects, including amounts, status, or timelines.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.